Monday, February 28, 2022
10:44 AM EST – BriaCell Therapeutics Corp. : Has recruited two additional clinical sites for screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat. The additional clinical sites include the following: 1) Atlantic Health System, Morristown, New Jersey, and 2) Tranquil Clinical Research, Webster, Texas. BriaCell Therapeutics Corp. (T.BCT) shares were up $0.18 at 9.86.
Stocks in Play: BriaCell Therapeutics Corp., Mon, 28 Feb 2022 10:57:07 EST